Quest Diagnostics Inc vs Fubotv Inc — how do they compare? Quest Diagnostics Inc trades at $203.55 (market cap $22.80B), while Fubotv Inc trades at $10.08 (market cap $280.89M). The key difference: Quest Diagnostics Inc is far larger — about 81.2× Fubotv Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| DGX | FUBO | |
|---|---|---|
Market Cap | $22.80B | $280.89M |
Sector | Health | Technology |
52-Week High | $216.02 | $54.72 |
52-Week Low | $166.42 | $8.09 |
Enterprise Value | $28.82B | $451.31M |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
FUBO trades at $9.83, up 7.08% today, with technical indicators showing neutral signals. The company reported a net loss of $172.25M in 2024, but revenue grew to $1.62B and net income is projected to turn positive in 2025. Recent CEO appointment from Disney has driven positive sentiment, while valuation ratios like P/E of 2.56 and P/S of 0.2 appear attractive relative to historical norms.
Outlook is cautiously optimistic with analyst consensus price target of $16.25 implying 65% upside, supported by streaming growth and new partnerships. Key risks include persistent cash burn and intense competition in the streaming sector. The stock offers value if profitability targets are met, but requires monitoring of subscriber trends and execution on cost controls.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →